# Plasma Levels of MicroRNA Let-7c-5p May Predict Risk of Acute Chest Syndrome in Patients with Sickle Cell Disease

## TL;DR

Higher levels of a specific microRNA in the blood may predict the risk of a severe complication in sickle cell disease patients.

## Contribution

The study identifies plasma let-7c-5p as a potential biomarker for predicting acute chest syndrome in sickle cell disease.

## Key findings

- Plasma let-7c-5p levels were twofold higher in patients without a history of acute chest syndrome.
- Let-7c-5p levels correlated positively with the time to subsequent acute chest syndrome events.
- Let-7c-5p may contribute to endothelial disruption in acute chest syndrome pathogenesis.

## Abstract

Acute chest syndrome (ACS) is among the most serious complications of sickle cell disease (SCD). While the pathogenesis of ACS is incompletely understood, endothelial damage and microvascular occlusion are critical components. Our previous studies have implicated small extracellular vesicles in the plasma of subjects with SCD in causing endothelial dysfunction. This suggested that microRNAs within these small EVs might be responsible for endothelial damage. The sequencing of microRNAs in small EVs from the plasma of subjects with SCD revealed that several miRNAs were differentially expressed between subjects with and without ACS history, including let-7c-5p. In a replication cohort, plasma let-7c-5p levels were quantified via RT-qPCR. The baseline plasma let-7c-5p level was twofold higher in patients without previous ACS. Furthermore, we observed a positive correlation between let-7c-5p levels and time to subsequent ACS events. These findings suggest a role for let-7c-5p in endothelial disruption underlying ACS pathogenesis. It may also serve as a novel biomarker for ACS detection and the prediction of disease progression.